trans-Cyclopentan-1,2-dicarbonsaeure | 1461-97-8

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: trans-Cyclopentan-1,2-dicarbonsaeure
• 英文别名: (R.R)-Cyclopentan-1.2-dicarbonsaeure；(1R,2R)-cyclopentane-1,2-dicarboxylic acid；trans-Cyclopentan-dicarbonsaeure-(1,2)；trans-Cyclopentane-1,2-dicarboxylic acid
• CAS: 1461-97-8
• 化学式: C₇H₁₀O₄
• 分子量: 158.154
• InChiKey: ASJCSAKCMTWGAH-RFZPGFLSSA-N

物化性质

• 熔点：
  163-165 °C(lit.)
• 沸点：
  46-49 °C(Press: 110 Torr)
• 密度：
  1.396±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二甲基亚砜；甲醇
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 危险品运输编号：
  NONH for all modes of transport
• 储存条件：
  常温、避光、存放在通风干燥处。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : trans-DL-1,2-Cyclopentanedicarboxylic acid
CAS-No. : 1461-97-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C7H10O4
Molecular Weight : 158,15 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 163 - 165 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong acids, Strong bases
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用作药物格列奇特的中间体。

反应信息

• 作为反应物：
  描述：

  trans-Cyclopentan-1,2-dicarbonsaeure 在 lithium aluminium tetrahydride 作用下， 生成 1,2-dimethylenecyclopentane
  参考文献：
  名称：

  Cycloaddition. VII. Competitive 1,2- and 1,4-addition to cis-fixed cyclic dienes

  摘要：

  DOI：

  10.1021/ja01024a023
• 作为产物：
  描述：

  (1R,2S)-cis-2-methoxycarbonyl-cyclopentane-1-carboxylic acid 在 sodium hydroxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 8.0h， 生成 trans-Cyclopentan-1,2-dicarbonsaeure
  参考文献：
  名称：

  Asymmetric synthesis of chiral bisoxazolines and their use as ligands in metal catalysis

  摘要：

  Novel C-2- and C-1-symmetric chiral bisoxazolines with a cyclic backbone have been synthesized in an asymmetric manner starting from ineso anhydrides. All synthetic steps are easy to perform and lead to the desired products in good overall yields. Preliminary investigations revealed the applicability of these new compounds as ligands in transfer hydrogenations and various metal-catalyzed enantioselective C-C-bond forming reactions such as cyclopropanations and Diels-Alder reactions. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2005.12.036

文献信息

• METHOD FOR PRODUCING CARBOXYLIC ANHYDRIDE AND ARYLBORONIC ACID COMPOUND
  申请人：Ishihara Kazuaki

  公开号：US20110319620A1

  公开（公告）日：2011-12-29

  When phthalic acid is heated in heptane under azeotropic reflux conditions in the presence of a catalytic amount of an arylboronic acid compound (such as 2,6-(diisopropylaminomethyl)phenylboronic acid or 2,6-bis(diisopropylaminomethyl)phenylboronic acid), phthalic anhydride is obtained in high yield.

  当邻苯二甲酸在庚烷中，在存在催化量的芳基硼酸化合物（如2,6-(二异丙氨基甲基)苯硼酸或2,6-双(二异丙氨基甲基)苯硼酸）的条件下，进行共沸回流加热时，可以获得高产率的邻苯二甲酸酐。
• Anti-AIDS Agents 81. Design, Synthesis, and Structure−Activity Relationship Study of Betulinic Acid and Moronic Acid Derivatives as Potent HIV Maturation Inhibitors
  作者：Keduo Qian、Reen-Yun Kuo、Chin-Ho Chen、Li Huang、Susan L. Morris-Natschke、Kuo-Hsiung Lee

  DOI：10.1021/jm901782m

  日期：2010.4.22

  as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3′ dimethyl group of bevirimat (2), the first-in-class HIV maturation inhibitor

  在我们将三萜衍生物作为有效抗 HIV 药物的持续研究中，设计并合成了不同的 C-3 构象限制桦木酸 (BA, 1 ) 衍生物，以探索 C-3 药效团的构象空间。还设计了3 - O-单甲基琥珀酰-桦木酸 (MSB) 类似物以更好地了解 beviriMAt ( 2 )的 C-3' 二甲基基团的贡献，beviriMAt ( 2 ) 是一流的 HIV 成熟抑制剂，目前处于 IIb 期临床试验。此外，另一种三萜骨架，吗啉酸（MA，3)，还用于研究骨架和 C-3 修饰对此类化合物的抗 HIV 活性的影响。这项研究使我们能够更好地了解三萜衍生的抗 HIV 药物的构效关系 (SAR)，并导致化合物12 (EC 50 : 0.0006 μM)的设计和合成，其活性略好于2作为HIV-1 成熟抑制剂。
• CURING AGENTS FOR EPOXY RESINS
  申请人：Dershem Stephen M

  公开号：US20130012620A1

  公开（公告）日：2013-01-10

  The present invention relates to curatives for epoxy resins, and compositions (e.g. adhesives) containing such resins cured using the same methods of preparation and uses therefor. More specifically, the present invention relates to hybrid curatives for epoxy resins comprising both aromatic amine, phenol and/or phenyl ester moieties. A further aspect of the current invention relates to new imidazole catalysts that possess a combination of excellent cure latency as well as low cure temperature onset.

  本发明涉及环氧树脂的硬化剂，以及含有经相同制备方法固化的这种树脂的组合物（例如胶粘剂）及其用途。更具体地，本发明涉及用于环氧树脂的混合硬化剂，包括芳香胺、酚和/或苯酯基团。本发明的另一个方面涉及具有优异固化潜伏期和低固化温度起始点的新咪唑催化剂。
• Catalytic Enantioselective Conjugate Addition of Cyanide to α,β-Unsaturated <i>N</i>-Acylpyrroles
  作者：Tsuyoshi Mita、Kazuki Sasaki、Motomu Kanai、Masakatsu Shibasaki

  DOI：10.1021/ja043424s

  日期：2005.1.1

  enantioselective conjugate addition of cyanide to α,β-unsaturated N-acylpyrroles was developed using the chiral gadolinium catalyst generated from Gd(OiPr)3 and d-glucose-derived ligand 2. Generally high enantioselectivity was obtained from a wide range of substrates; substrates with β-aryl and β-vinyl substituents and α,β-disubstituted substrates can now be used. Using this reaction as a key step, short-step

  使用由 Gd(OiPr)3 和 d-葡萄糖衍生的配体 2 生成的手性钆催化剂开发了氰化物与 α,β-不饱和 N-酰基吡咯的催化对映选择性共轭加成。 通常从广泛的底物获得高对映选择性; 现在可以使用带有 β-芳基和 β-乙烯基取代基的底物以及 α,β-二取代的底物。使用该反应作为关键步骤，实现了几种药物及其先导化合物的短步合成，包括 β-苯基取代的 GABA 类似物和普瑞巴林。
• [EN] CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS<br/>[FR] ACIDES HYDROXAMIQUES CYCLIQUES UTILISES EN TANT QU'INHIBITEURS DE METALLOPROTEASES
  申请人：DU PONT PHARMACEUTICALS COMPANY

  公开号：WO1999065867A1

  公开（公告）日：1999-12-23

  (EN) The present application describes novel cyclic hydroxamic acids of formula (I): or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.(FR) La présente invention se rapporte à de nouveaux acides hydroxamiques cycliques représentés par la formule (I) ou à des sels pharmaceutiquement acceptables de ces acides. Dans la formule (I), le noyau B est un système cyclique comportant 5 à 7 éléments possédant 0 à 2 hétéroatomes sélectionnés parmi O, N, NRa, et S(O)p, et 0 à 1 groupe carbonyle, et les autres variables sont définies dans la description associée à la présente invention. Ces acides s'avèrent utiles en tant qu'inhibiteurs de métalloprotéases.

  本申请描述了新型的环状羟肟酸式化合物(I)或其药学上可接受的盐形式，其中环B是一个包含0-2个来自O、N、NRa和S(O)p的杂原子和0-1个羰基的5-7元环系统，其他变量在本说明书中定义，这些化合物可用作金属蛋白酶抑制剂。